Overcoming Current Obstacles in the Management of Bacterial Community-Acquired Pneumonia in Ambulatory Children

Abstract

Get full access to this article

View all access options for this article.

References

McIntosh K . Community-acquired pneumonia in children. N Engl J Med. 2002;346:429-437.

Jadavji T , Law B , Lebel MH , et al. A practical guide for the diagnosis and treatment of pediatric pneumonia. CMAJ. 1997;156:S703-S711.

Ruuskanen O , Mertsola J . Childhood community-acquired pneumonia. Semin Respir Infect. 1999;14:163-172.

British Thoracic Society Standards of Care Committee . British Thoracic Society guidelines for the management of community acquired pneumonia in childhood. Thorax. 2002;57(Suppl. 1):i1-i24.

Nelson JD . Community-acquired pneumonia in children: guidelines for treatment. Pediatr Infect Dis J. 2000;19:251-253.

McCracken GH . Diagnosis and management of pneumonia in children. Pediatr Infect Dis J. 2000;19:924-928.

World Health Organization (WHO) . Clinical management of acute respiratory infections in children: a WHO memorandum. Bull World Health Organ. 1981;59:707-716.

Foy HM , Cooney MK , Allan I , et al. Rates of pneumonia during influenza epidemics in Seattle, 1964-1975. JAMA. 1979;241:253-258.

Murphy TF , Henderson FW , Clyde WA Jr , et al. Pneumonia: an eleven-year study in a pediatric practice. Am J Epidemiol. 1981;113:12-21.

10.

McConnochie KM , Hall CB , Barker WH . Lower respiratory tract illness in the first two years of life: epidemiologic patterns and costs in a suburban pediatric practice. Am J Public Health. 1988;78:34-39.

11.

Jokinen C , Heiskanen L , Juvonen H , et al. Incidence of community-acquired pneumonia in the populations of four municipalities in eastern Finland. Am J Epidemiol. 1993;137:977-988.

12.

Davidson M , Parkinson AJ , Bulkow LR , et al. The epidemiology of invasive pneumococcal disease in Alaska, 1986-1990—ethnic differences and opportunities for prevention. JInfect Dis. 1994;170:368-376.

13.

Black SB , Shinefield HR , Ling S , et al. Effectiveness of heptavalent pneumococcal vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21:810-815.

14.

Korppi M , Heiskanen-Kosma T , Jalonen E , et al. Aetiology of community-acquired pneumonia in children treated in hospital. Eur J Pediatr. 1993;152:24-30.

15.

Gil A , San-Martin M , Carrasco P , et al. Epidemiology of pneumonia hospitalizations in Spain, 1995-1998. J Infect. 2002;44:84-87.

16.

Lieberman D , Lieberman D , Friger MD . Seasonal variation in hospital admissions for community-acquired pneumonia: a 5-year study. J Infect. 1999;39:134-140.

17.

Selwyn BJ . The epidemiology of acute respiratory tract infection in young children: comparison of findings from several developing countries. Rev Infect Dis. 1990;12(Suppl. 8):S870-S888.

18.

Singh GK , Yu SM . Infant mortality in the United States: trends, differentials, and projections, 1950 through 2010. Am J Public Health. 1995;5:957-964.

19.

Dowell SF , Kupronis BA , Zell ER , et al. Mortality from pneumonia in children in the United States, 1939 through 1996. N Engl J Med. 2000;342:1399-1407.

20.

Murray CL , Lopez AD . Global and regional cause-of-death patterns in 1990. Bull World Health Organ. 1994;72:447-480.

21.

Wubbel L , Muniz L , Ahmed A , et al. Etiology and treatment of community-acquired pneumonia in ambulatory children. Pediatr Infect Dis J. 1999;18:98-104.

22.

Heiskanen-Kosma T , Korppi M , Jokinen C , et al. Etiology of childhood pneumonia: serologic results of a prospective, population-based study. Pediatr Infect Dis J. 1998;17:986-991.

23.

Saikku P , Ruutu P , Leinonen M , et al. Mycoplasma pneumoniae and Chlamydia trachomatis in acute lower respiratory infections in Filipino children. Am J Trop Med Hyg. 1993;49:88-92.

24.

Gendrel D , Raymond J , Moulin F , et al. Etiology and response to antibiotic therapy of community-acquired pneumonia in French children. Eur J Clin Microbiol Infect Dis. 1997;16:388-391.

25.

Esposito S , Blasi F , Bellini F , et al. Mycoplasma pneumoniae and Chlamydia pneumoniae infections in children with pneumonia. Eur Respir J. 2001;17:241-245.

26.

Principi N , Esposito S , Blasi F , et al. Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections. Clin Infect Dis. 2001;32:1281-1289.

27.

Block S , Hedrick J , Hammerschlag MR , et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in paediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs erythromycin vs erythromycin ethylsuccinate. Pediatr Infect Dis J. 1995;14:471-477.

28.

Harris JA , Kolokathis A , Campbell M , et al. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr Infect Dis J. 1998;17:865-871.

29.

Djuretic T , Ryan MJ , Miller E , et al. Hospital admissions in children due to pneumococcal pneumonia in England. J Infect. 1998;37:54-58.

30.

Juven T , Mertsola J , Waris M , et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J. 2000;19:293-298.

31.

Tan TQ , Mason EO Jr , Wald ER , et al. Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae. Pediatrics. 2002;110:1-6.

32.

Trujillo M , McCracken GH . Prolonged morbidity in children with group A beta-hemolytic streptococcal pneumonia. Pediatr Infect Dis J. 1994;13:411-412.

33.

Drummond P , Clark J , Wheeler J , et al. Community acquired pneumonia—a prospective UK study. Arch Dis Child. 2000;83:408-412.

34.

Nascimento-Carvalho CM . Etiology of childhood community-acquired pneumonia and its implications for vaccination. Braz J Infect Dis. 2001;5:87-97.

35.

Broughton RA . Infections due to Mycoplasma pneumoniae in childhood. Pediatr Infect Dis J. 1986;5:71-85.

36.

McCarthy PL , Spiesel SZ , Stashwick CA , et al. Radiographic findings and etiological diagnosis in ambulatory childhood pneumonias. Clin Pediatr. 1981;20:686-691.

37.

Korppi M , Kiekara O , Heiskanen-Kosma T , et al. Comparison of radiological findings and microbial aetiology of childhood pneumonia. Acta Paediatr. 1993;82:360-363.

38.

Virkki R , Juven T , Rikalainen H , et al. Differentiation of bacterial and viral pneumonia in children. Thorax. 2002;57:438-441.

39.

Dowell SF , Peeling RW , Boman J , et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis. 2001;33:492-503.

40.

Smith PR . What diagnostic tests are needed for community-acquired pneumonia? Med Clin North Am. 2001;85:1381-1396.

41.

Verkooyen RP , Willemse D , Hiep SC , et al. Evaluation of PCR, culture and serology tests for diagnosis of Chlamydia pneumoniae respiratory infections. J Clin Microbiol. 1998;36:2301-2307.

42.

Waris M , Toikka P , Saarinen T , et al. Diagnosis of Mycoplasma pneumoniae pneumonia in children. J Clin Microbiol. 1998;36:3155-3159.

43.

Michelow IC , Lozano J , Olesen K , et al. Diagnosis of Streptococcus pneumoniae lower respiratory tract infection in hospitalized children by culture, polymerase chain reaction, serological testing, and urinary antigen detection. Clin Infect Dis. 2002;34:E1-E11.

44.

Hyman CL , Roblin PM , Gaydos CA , et al. Prevalence of asymptomatic nasopharyngeal carriage of Chlamydia pneumoniae in subjectively healthy adults: assessment by polymerase chain reaction-enzyme immunoassay and culture. Clin Infect Dis. 1995;20:1174-1178.

45.

Kutlin A , Roblin PM , Hammerschlag MR . Antibody response to Chlamydia pneumoniae infection in children with respiratory illness. J Infect Dis. 1998;177:720-724.

46.

Apfalter P , Blasi F , Boman J , et al. Multicenter comparison trial of DNA extraction methods and PCR assays for detection of Chlamydia pneumoniae in endarterectomy specimens. J Clin Microbiol. 2001;39:519-524.

47.

Apfalter P , Assadian O , Blasi F , et al. Reliability of nested PCR for detection of Chlamydia pneumoniae DNA in atheromas: results from a multicenter study applying standardized protocols. J Clin Microbiol. 2002;40:4428-4434.

48.

Boman J , Hammerschlag MR . Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies. Clin Microbiol Rev. 2002;15:1-20.

49.

Hammerschlag MR , Reznik T , Roblin PM , et al. Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. J Antimicrob Chemother. 2003;51:1025-1028.

50.

Gaydos CA , Roblin PM , Hammerschlag MR , et al. Diagnostic utility of PCR-EIA, culture and serology for detection of Chlamydia pneumoniae in symptomatic and asymptomatic patients. J Clin Microbiol. 1994;32:903-905.

51.

Weiss KB , Wagner KD . Changing patterns of asthma mortality: identifying target populations at high risk. JAMA. 1990;264:683-685.

52.

Clark CE , Coote JM , Silver DA , et al. Asthma after childhood pneumonia: six-year follow-up study. BMJ. 2000;320:1514-1516.

53.

Micillo E , Bianco A , D’Auria D , et al. Respiratory infections and asthma. Allergy. 2000;55:(Suppl. 61):42-45.

54.

Emre U , Roblin PM , Gelling M , et al. The association of Chlamydia pneumoniae infection and reactive airway disease in children. Arch Pediatr Adolesc Med. 1994;148:727-732.

55.

Esposito S , Blasi F , Arosio C , et al. Importance of acute Mycoplasma pneumoniae and Chlamydia pneumoniae infections in children with wheezing. Eur Respir J. 2000;16:1142-1146.

56.

Esposito S , Principi N . Asthma in children: are chlamydia or mycoplasma involved? Paediatr Drugs. 2001;3:159-168.

57.

Platt OS , Brambilla DJ , Rosse WF , et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639-1644.

58.

Vichinsky EP . Comprehensive care in sickle cell disease: its impact on morbidity and mortality. Semin Hematol. 1991;28:220-226.

59.

Gray A , Anionwu EN , Davies SC , et al. Patterns of mortality in sickle cell disease in the United Kingdom. J Clin Pathol. 1991;44:459-463.

60.

Thomas AN , Pattison C , Serjeant GR . Causes of death in sickle-cell disease in Jamaica. BMJ. 1982;285:633-635.

61.

Vichinsky EP , Styles LA , Colangelo LH , et al. Acute chest syndrome in sickle cell disease: clinical presentation and course. Blood. 1997;89:1787-1792.

62.

Vichinsky EP , Neumayr LD , Earles AN , et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med. 2000;342:1855-1865.

63.

Miller ST , Hammerschlag MR , Chirgwin K , et al. Role of Chlamydia pneumoniae in acute chest syndrome of sickle cell disease. J Pediatr. 1991;118:30-33.

64.

Srair HA , Owa JA , Aman HA , et al. Acute chest syndrome in children with sickle cell disease. Indian J Pediatr. 1995;62:201-205.

65.

De Ceulaer K , McMullen KW , Maude GH , et al. Pneumonia in young children with homozygous sickle cell disease: risk and clinical features. Eur J Pediatr. 1985;144:255-258.

66.

Shulman ST , Bartlett J , Clyde WA Jr , et al. The unusual severity of mycoplasmal pneumonia in children with sickle-cell disease. N Engl J Med. 1972:287:164-167.

67.

Dean D , Neumayr L , Kelly DM , et al. Chlamydia pneumoniae and acute chest syndrome in patients with sickle cell disease. J Pediatr Hematol Oncol. 2003;25:46-55.

68.

Felmingham D , Feldman C , Hryniewicz W , et al. Surveillance of resistance in bacteria causing community-acquired respiratory tract infections. Clin Microbiol Infect. 2002;8(Suppl. 2):12-42.

69.

Metlay JP , Singer DE . Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance. Clin Microbiol Infect. 2002;8(Suppl. 2):1-11.

70.

Doern GV , Heilmann KP , Huynh HK , et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother. 2001;45:1721-1729.

71.

Friedland IR . Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr Infect Dis J. 1995;14:885-890.

72.

Choi EH , Lee HJ . Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children. Clin Infect Dis. 1998;26:1346-1354.

73.

Deeks SL , Palacio R , Ruvinksy R , et al. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. Pediatrics. 1999;103:409-413.

74.

Gómez-Barreto D , Calderón-Jaimes E , Rodríguez RS , et al. Clinical outcome of invasive infections in children caused by highly penicillin-resistant Streptococcus pneumoniae compared with infections caused by penicillin-susceptible strains. Arch Med Res. 2000;31:592-598.

75.

Piroth L , Martin L , Coulon A , et al. Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics. Antimicrob Agents Chemother. 1999;43:2484-2492.

76.

National Committee for Clinical Laboratory Standards (NCCLS) . Performance Standards for Antimicrobial Sensitivity Testing. Document M100-S13. Wayne, PA: NCCLS; 2003.

77.

Tan TQ , Mason EO Jr , Barson WJ , et al. Clinical characteristics and outcome of children with pneumonia attributable to penicillin-susceptible and penicillin-nonsusceptible Streptococcus pneumoniae. Pediatrics. 1998;102:1369-1375.

78.

Pallares R , Liñares J , Vadillo M , et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. 1995;333:474-480.

79.

Dowell SF , Smith T , Leversedge K , et al. Pneumonia treatment failure associated with highly resistant pneumococci. Clin Infect Dis. 1999;29:462-463.

80.

Ewig S , Ruiz M , Torres A , et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med. 1999;159:1835-1842.

81.

Garau J , Aguilar L , Rodriguez-Creixems M , et al. Influence of comorbidity and severity on the clinical outcome of bacteremic pneumococcal pneumonia treated with β-lactam monotherapy. J Chemother. 1999;11:266-272.

82.

Metlay JP , Hofmann J , Cetron MS , et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2000;30:520-528.

83.

Moroney JF , Fiore AE , Harrison LH , et al. Clinical outcomes of bacteraemic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis. 2001;33:797-805.

84.

Heffelfinger JD , Dowell SF , Jorgensen JH , et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med. 2000;160:1399-1408.

85.

Zhanel GG , Dueck M , Hoban DJ , et al. Review of macrolides and ketolides: focus on respiratory tract infections. Drugs. 2001;61:443-498.

86.

Amsden GW . Erythromycin, clarithromycin, and azithromycin: are the differences real? Clin Ther. 1996;18:56-72.

87.

Lynch JP , Martinez FJ . Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis. 2003;34(Suppl. 1):S27-S46.

88.

Amsden GW . Pneumococcal macrolide resistance—myth or reality? J Antimicrob Chemother. 1999;44:1-6.

89.

Veber B , Vallee E , Desmonts JM , et al. Correlation between macrolide lung pharmacokinetics and therapeutic efficacy in a mouse model of pneumococcal pneumonia. J Antimicrob Chemother. 1993;32:473-482.

90.

Tessier PR , Kim MK , Zhou W , et al. Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob Agents Chemother. 2002:46:1425-1434.

91.

Berry V , Thorburn CE , Knott SJ , et al. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob Agents Chemother. 1998;42:3193-3199.

92.

Carbon C , Poole MD . The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. J Chemother. 1999;11:107-118.

93.

Farrell DJ , Morrissey I , Bakker S , et al. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. J Antimicrob Chemother. 2002;50 (Suppl. S1):39-47.

94.

Musher DM , Dowell ME , Shortridge VD , et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med. 2002;346:630-631.

95.

Deligne B , Turgeon PL , Fleury C , et al. Are macrolides still appropriate for empiric therapy of community-acquired pneumonia? In Proceedings and Abstracts of the 41st Interscience Congress on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001. Abstract L-1484. Washington, DC: American Society of Microbiology; 2001:472.

96.

Lonks JR , Garau J , Gomez L , et al. Failure of macrolide treatment of erythromycin-resistant Streptococcus pneumoniae. In Proceedings and Abstracts from the 41st Interscience Congress on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001. Abstract L-1850. Washington, DC: American Society for Microbiology; 2001:473.

97.

Kays MB , Wack MF , Smith DW , et al. Azithromycin treatment failure in community-acquired pneumonia caused by Streptococcus pneumoniae resistant to macrolides by a 23S rRNA mutation. Diagn Microbiol Infect Dis. 2002;43:163-165.

98.

Garau J , Lonks JR , Gomez L , et al. Failure of macrolide therapy in patients with bacteraemia due to macrolide resistant Streptococcus pneumoniae. In Program and Abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones, Seville, Spain, 2000. Abstract 7.09. Georgia: ICMAS Inc.; 2000:65.

99.

Waterer GW , Wunderink RG , Jones CB . Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest. 2000;118:1839-1840.

100.

Van Kerkhoven D , Peetermans WE , Verbist L , et al. Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams. J Antimicrob Chemother. 2003;51:691-696.

101.

Fogarty C , Goldschmidt R , Bush K . Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis. 2000;31:613-615.

102.

Kelley MA , Weber DJ , Gilligan P , et al. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis. 2000;31:1008-1011.

103.

Hyde TB , Gay K , Stephens DS , et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA. 2001;286:1857-1862.

104.

Roblin PM , Montalban G , Hammerschlag MR . Susceptibility to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. Antimicrob Agents Chemother. 1994;38:1588-1589.

105.

Roblin PM , Hammerschlag MR . Microbiologic efficacy of azithromycin and susceptibility to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. Antimicrob Agents Chemother. 1998;42:194-196.

106.

Lee LH , Lee CJ , Frasch CE . Development and evaluation of pneumococcal conjugate vaccines: clinical trials and control tests. Crit Rev Microbiol. 2002;28:27-41.

107.

Heath PT , Booy R , Azzopardi HJ , et al. Non-type b Haemophilus influenzae disease: clinical and epidemiologic characteristics in the Haemophilus influenzae type b vaccine era. Pediatr Infect Dis J. 2001;20:300-305.

108.

Eskola J , Kilipi T , Palmu A , et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403-409.

109.

Paes BA . Current strategies in the prevention of respiratory syncytial virus disease. Pediatr Respir Rev. 2003;4:21-27.

110.

Zhanel GG , Walters M , Noreddin A , et al. The ketolides: a critical review. Drugs. 2002;62:1771-1804.

111.

Felmingham D . Microbiological profile of telithromycin, the first ketolide antimicrobial. Clin Microbiol Infect. 2001;7(Suppl. 3):2-10.

112.

Hammerschlag MR , Roblin PM , Bébéar CM . Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens. J Antimicrob Chemother. 2001;48(Suppl. T1):25-31.

113.

Leclercq R . Will resistance to ketolides develop in Streptococcus pneumoniae? J Infect. 2002;44(Suppl. A):11-16.

114.

Nicolau DP . Pharmacodynamic rationale for short-duration antibacterial therapy. J Infect. 2002;44(Suppl. A):17-23.

115.

Carbon C , Moola S , Velancsics I , et al. Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia. Clin Microbiol Infect. 2003;9:691-703.

116.

Hagberg L , Carbon C , van Rensburg DJ , et al. Telithromycin in the treatment of community-acquired pneumonia: a review. Respir Med. 2003;97:625-633.

117.

Mandell LA , Petersen LR , Wise R , et al. The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children? Clin Infect Dis. 2002;35:721-727.

118.

Chen DK , McGeer A , de Azavedo JC , et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med. 1999;341:233-239.

119.

Davidson R , Cavalcanti R , Brunton JL , et al. Levofloxacin treatment failures of pneumococcal pneumonia in association with resistance. N Engl J Med. 2002;346:747-750.

120.

Goldstein EJ , Garabedian-Ruffalo SM . Widespread use of fluoroquinolones versus emerging resistance in pneumococci. Clin Infect Dis. 2002;35:1505-1511.

121.

Quale J , Landman D , Ravishankar J , et al. Streptococcus pneumoniae, Brooklyn, New York: fluoroquinolone resistance at our doorstep. Emerg Infect Dis. 2002;8:594-597.

122.

Morrissey I , Farrell DJ , Bakker S , et al. Molecular characterization and antimicrobial susceptibility of fluoroquinolone-resistant or -susceptible Streptococcus pneumoniae from Hong Kong. Antimicrob Agents Chemother. 2003;47:1433-1435.